Content about Bronchitis

May 21, 2012
Screening for COPD

DSN recently talked with COPD Foundation founder and president John Walsh about the organization's new leadership. In March, the COPD Foundation took over leadership for Drive4COPD, which aims to screen people for chronic obstructive pulmonary disease, a collective term for emphysema and chronic bronchitis, which the group estimates to affect 24 million Americans who may have it but don't know it.

AUDIO Q&A: DSN recently talked with COPD Foundation founder and president John Walsh about the organization's new leadership. In March, the COPD Foundation took over leadership for Drive4COPD, which aims to screen people for chronic obstructive pulmonary disease, a collective term for emphysema and chronic bronchitis, which the group estimates to affect 24 million Americans who may have it but don't know it.

May 23, 2012
COPD spurs drug development

Taken together, asthma and chronic obstructive pulmonary disease — which includes chronic bronchitis and emphysema — affect nearly 50 million Americans, or about 15% of the total U.S. population, according to statistics from such organizations as the Centers for Disease Control and Prevention. And combined, the two diseases cause more than 100,000 deaths per year. Fortunately, however, there is a wide range of treatments available for both, many of which work for both diseases.

Taken together, asthma and chronic obstructive pulmonary disease — which includes chronic bronchitis and emphysema — affect nearly 50 million Americans, or about 15% of the total U.S. population, according to statistics from such organizations as the Centers for Disease Control and Prevention. And combined, the two diseases cause more than 100,000 deaths per year. Fortunately, however, there is a wide range of treatments available for both, many of which work for both diseases.

March 20, 2012
Novartis launches Arcapta Neohaler

Novartis has launched a new treatment for chronic obstructive pulmonary disease, the drug maker said Monday.

EAST HANOVER, N.J. — Novartis has launched a new treatment for chronic obstructive pulmonary disease, the drug maker said Monday.

Novartis Pharmaceuticals, the U.S. division of the Swiss drug manufacturer, announced the launch of Arcapta Neohaler (indacaterol inhalation powder) in the 75-mcg strength. The Food and Drug Administration approved the drug last July.

February 2, 2012
PhRMA: More than 50 drugs in development for COPD

More than 50 drugs are under development for treating a respiratory disease that is the third-leading cause of death in the United States.

WASHINGTON — More than 50 drugs are under development for treating a respiratory disease that is the third-leading cause of death in the United States.

The Pharmaceutical Research and Manufacturers of America released a list Thursday of 54 drugs in clinical development for chronic obstructive pulmonary disease, or COPD.

July 5, 2011
Novartis receives FDA approval for COPD drug

The Food and Drug Administration has approved a drug made by Novartis for treating chronic obstructive pulmonary disease, the FDA said Friday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a drug made by Novartis for treating chronic obstructive pulmonary disease, the FDA said Friday.

The FDA approved Arcapta Neohaler (indacaterol inhalation powder) for long-term, once-daily maintenance of bronchodilator treatment of airflow obstruction in people with COPD, including chronic bronchitis and emphysema.

COPD, which often results from cigarette smoking, is the fourth-leading cause of death in the United States, according to the Centers for Disease Control and Prevention.

June 10, 2011
Forest announces availability of Daliresp

A drug for chronic obstructive pulmonary disease made by Forest Labs will be available by the middle of this month, Forest said Thursday.

NEW YORK — A drug for chronic obstructive pulmonary disease made by Forest Labs will be available by the middle of this month, Forest said Thursday.

Daliresp (roflumilast) recently received approval from the Food and Drug Administration as a treatment to reduce the risk of exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.

Forest said Daliresp, a daily oral tablet, is the first and only approved drug in its class, known as selective phosphodiesterase-4 inhibitors.

March 24, 2011
FDA extends NDA review for Novartis' COPD treatment

The Food and Drug Administration has extended its regulatory review period for Novartis' new drug application for its once-daily, long-term maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, as well as chronic bronchitis and/or emphysema, the drug maker said.

BASEL, Switzerland — The Food and Drug Administration has extended its regulatory review period for Novartis' new drug application for its once-daily, long-term maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, as well as chronic bronchitis and/or emphysema, the drug maker said.

March 1, 2011
Forest gets nod for COPD drug

The Food and Drug Administration has approved a treatment for chronic obstructive pulmonary disease made by Forest Labs, the agency said Tuesday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a treatment for chronic obstructive pulmonary disease made by Forest Labs, the agency said Tuesday.

February 2, 2011
Drive4COPD achieves record

A coalition of companies, celebrities and health organizations has achieved its goal of screening 1 million Americans for risk of chronic obstructive pulmonary disease.

RIDGEFIELD, Conn. — A coalition of companies, celebrities and health organizations has achieved its goal of screening 1 million Americans for risk of chronic obstructive pulmonary disease.

Drive4COPD announced the milestone Wednesday, saying its aim was to change how COPD is addressed in the United States; Drive4COPD identified those at risk through its COPD Population Screener.

December 10, 2010
COPD now No. 3 leading cause of death among Americans

Chronic obstructive pulmonary disease is the third-leading cause of death in the United States, according to a new report by the Centers for Disease Control and Prevention.

WASHINGTON — Chronic obstructive pulmonary disease is the third-leading cause of death in the United States, according to a new report by the Centers for Disease Control and Prevention.

The CDC’s National Center for Health Statistics released the report Friday, which showed that COPD became the third-leading cause of death in 2008, but it was expected to reach that rank in 2020. COPD is a collective term for such respiratory diseases as emphysema, chronic bronchitis and bronchiectasis, and affects around 24 million Americans.

November 16, 2010
COPD patients express hardships in new GSK study

Patients living with chronic obstructive pulmonary disease said the illness prevented them from living life...

RESEARCH TRIANGLE PARK, N.C. Patients living with chronic obstructive pulmonary disease said the illness prevented them from living life to its fullest, according to research conducted by drug maker GlaxoSmithKline.

 

January 11, 2010
Galapagos, Roche to develop COPD treatments

A Belgian biotech company plans to work with Swiss drug maker Roche to develop treatments...